Stock Market & Financial Investment News

Novo Nordisk reports Q1 EPS down 10% to DKK 2.43Reports Q1 revenue up 7% in local currencies driven by Levemir and Victoza. Revenue increased by 7% in local currencies and by 2% in Danish kroner to DKK 20.3B. Operating profit increased by 15% in local currencies and by 6% in Danish kroner to DKK 8B.

Novo Nordisk to launch Novoeight in U.S. for people with Hemophilia A Novo Nordisk announced the company will launch Novoeight in the United States for people living with hemophilia A. Novoeight offers purity, reliability, and enhanced portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products—up to 86 degrees F for 12 months. It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time. Novoeight offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A. Novo Nordisk plans to make Novoeight available by mid-April.

Novo Nordisk says 3a trials achieved primary objectives Novo Nordisk announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset 1 and onset 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively. Both trials achieved their primary objectives by demonstrating that treatment with faster-acting insulin aspart is non-inferior to NovoRapid with regard to lowering of HbA1c. For people with type 1 diabetes, the HbA1c lowering achieved with faster-acting insulin aspart was statistically significantly larger than that achieved with NovoRapid when the insulins were given at mealtime. In addition, treatment with faster-acting insulin aspart was associated with less increase of postprandial glucose than NovoRapid during meal tests in both trials. In both trials, the previously reported safety and tolerability profiles of faster-acting insulin aspart and NovoRapid were confirmed, and there were no apparent differences between the two treatment groups with respect to adverse events and other safety parameters, Novo said.